CRL Stock Up 6.5% after 7-Day Win Streak
Charles River Laboratories International (CRL) stock hit day 7 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 6.5% return. The company has gained about $510 Mil in value over the last 7 days, with its current market capitalization at about $7.8 Bil. The stock remains 14.1% below its value at the end of 2024. This compares with year-to-date returns of 9% for the S&P 500.
CRL provides drug discovery, safety testing, and research models, along with early discovery services and in vitro testing for pharmaceuticals and consumer products. After this rally, is CRL still a buy – or is it time to lock in gains? Deep dive with Buy or Sell CRL.
Comparing CRL Stock Returns With The S&P 500
The following table summarizes the return for CRL stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | CRL | S&P 500 |
|---|---|---|
| 1D | 1.0% | -0.6% |
| 7D (Current Streak) | 6.5% | 0.3% |
| 1M (21D) | 5.8% | 1.7% |
| 3M (63D) | 12.1% | 7.5% |
| YTD 2025 | -14.1% | 9.0% |
| 2024 | -21.9% | 23.3% |
| 2023 | 8.5% | 24.2% |
| 2022 | -42.2% | -19.4% |
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades. However, big gains can follow sharp reversals – but how has CRL behaved after prior drops? See CRL Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 44 S&P constituents with 3 days or more of consecutive gains and 32 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 28 | 8 |
| 4D | 4 | 20 |
| 5D | 3 | 3 |
| 6D | 7 | 1 |
| 7D or more | 2 | 0 |
| Total >=3 D | 44 | 32 |
Key Financials for Charles River Laboratories International (CRL)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $4.1 Bil | $4.0 Bil |
| Operating Income | $617.3 Mil | $442.3 Mil |
| Net Income | $474.6 Mil | $10.3 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | $984.2 Mil | $1.0 Bil |
| Operating Income | $74.7 Mil | $100.1 Mil |
| Net Income | $25.5 Mil | $52.3 Mil |
While CRL stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.